CWM
NVO

Cranbrook Wealth Management’s Novo Nordisk NVO Stock Holding History

Cranbrook Wealth Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-110
Closed -$9.46K – 449
2024
Q4 		$9.46K Buy
110
+100
+1,000% +$10.8K ﹤0.01% 271
2024
Q3 		$1.19K Buy
+10
New +$1.33K ﹤0.01% 341

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Cranbrook Wealth Management's NVO Position: Q1 2025 in Review

Cranbrook Wealth Management sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 110 shares — an estimated $9.46K sold.

Cranbrook Wealth Management first reported a position in NVO in Q3 2024 and held it in 2 quarters. The position peaked at $9.46K in Q4 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Cranbrook Wealth Management reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Cranbrook Wealth Management sold 110 Novo Nordisk shares in Q1 2025, an estimated $9.46K.
  • Cranbrook Wealth Management first reported a position in Novo Nordisk in Q3 2024 and held it in 2 quarters.
  • Cranbrook Wealth Management's Novo Nordisk position peaked at $9.46K in Q4 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Cranbrook Wealth Management's 13F filing for Q1 2025, filed 11 Apr 2025.